Dr. Janakiraman Subramanian, MD ...

Dr. Janakiraman Subramanian

Claim this profile

Saint Luke's Hospital of Kansas City

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
10 reported clinical trials
20 drugs studied

Area of expertise

1Lung Cancer
Janakiraman Subramanian has run 9 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Janakiraman Subramanian has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
Saint Luke's Hospital Of Kansas City
Image of trial facility.
Saint Luke's East - Lee's Summit

Clinical Trials Janakiraman Subramanian is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria

More about Janakiraman Subramanian

Clinical Trial Related6 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Janakiraman Subramanian has experience with
  • Carboplatin
  • Pemetrexed
  • Pembrolizumab
  • Pemetrexed Disodium
  • Gemcitabine Hydrochloride
  • NovoTTF-200T

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Janakiraman Subramanian specialize in?
Is Janakiraman Subramanian currently recruiting for clinical trials?
Are there any treatments that Janakiraman Subramanian has studied deeply?
What is the best way to schedule an appointment with Janakiraman Subramanian?
What is the office address of Janakiraman Subramanian?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security